Dantrolene Sodium for Injection | more>>

Dantrolene Sodium for Injection is indicated, along with appropriate supportive measures, for the management of fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages. It is also indicated preoperatively and sometimes postoperatively, to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible. Malignant hyperthermia is life threatening and requires immediate medical attention and treatment.

Fatal and non-fatal liver disorders of an idiosyncratic or hypersensitivity type may occur with dantrolene sodium therapy. There have been reports of thrombophlebitis following administration of intravenous dantrolene. There have been rare reports of urticaria and erythema possibly associated with the administration of i.v. dantrolene sodium. Please see complete prescribing information for Dantrolene Sodium for Injection.

For More information on Malignant Hyperthermia please visit The Malignant Hyperthermia Association of the United States (MHAUS).

In Development

Lofexidine Hydrochloride | more>>

Lofexidine (for treatment of opiate withdrawal symptoms) is an alpha-2-adrenergic agonist which was licensed from Britannia Pharmaceuticals, Ltd of the United Kingdom. Lofexidine is being developed in the United States as a non-addictive, non-opiate treatment to manage the often debilitating withdrawal symptoms that occur during opiate detoxification. Lofexidine is not currently approved in the US. In support of a new drug application (NDA), US WorldMeds has recently launched a pivotal phase III clinical trial (USWM-001) to test the safety and efficacy of Lofexidine. US WorldMeds is currently recruiting 264 appropriate candidates across fourteen (14) clinical sites located throughout the United States. USWM-001 is an eight (8) day inpatient opiate detoxification with either Lofexidine or placebo.

For information on candidate requirements and locations of the clinical trial, please visit: http://www.clinicaltrials.gov/ct/show/NCT00235729?order=1.

To obtain contact information for the trial site nearest you, please call Kristen Marcum at +1 502 753 2095.

This is the place to look for US WorldMeds latest product releases as well as others in development. Our passion lies in bringing necessary medicines to the people at the most affordable prices.

US WorldMeds is proud to be a leader in bringing quality pharmaceuticals to everyone possible. We want to help the healthcare community provide the highest quality of life to as many patients as possible.